Dipeptidyl peptidase‐4 (DPP4) inhibitors (DPP4‐I) are oral glucose‐lowering drugs for type 2 diabetes mellitus. Previously, we reported that DPP4‐I (sitagliptin) exerted suppressive effects on experimental liver fibrosis in rats. Blockade… Click to show full abstract
Dipeptidyl peptidase‐4 (DPP4) inhibitors (DPP4‐I) are oral glucose‐lowering drugs for type 2 diabetes mellitus. Previously, we reported that DPP4‐I (sitagliptin) exerted suppressive effects on experimental liver fibrosis in rats. Blockade of the renin–angiotensin system by angiotensin‐II type 1 receptor blocker (losartan), commonly used in the management of hypertension, has been shown to significantly alleviate hepatic fibrogenesis and carcinogenesis. We aimed to elucidate the effects and possible mechanisms of a sitagliptin + losartan combination on the progression of non‐diabetic non‐alcoholic steatohepatitis (NASH) in a rat model.
               
Click one of the above tabs to view related content.